IRIS
PUGLISI, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.210
EU - Europa 3.595
AS - Asia 1.087
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 17
SA - Sud America 10
OC - Oceania 2
Totale 20.959
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.141
UA - Ucraina 1.235
CN - Cina 651
DE - Germania 563
IT - Italia 550
FI - Finlandia 349
SE - Svezia 303
IE - Irlanda 293
VN - Vietnam 145
TR - Turchia 125
IN - India 112
GB - Regno Unito 109
CA - Canada 69
BE - Belgio 48
TG - Togo 30
RO - Romania 24
IR - Iran 22
CH - Svizzera 21
PL - Polonia 21
RU - Federazione Russa 19
EU - Europa 16
FR - Francia 16
NL - Olanda 15
HK - Hong Kong 9
JP - Giappone 7
AT - Austria 6
KR - Corea 6
EG - Egitto 5
BR - Brasile 4
CO - Colombia 4
CZ - Repubblica Ceca 4
BG - Bulgaria 3
EE - Estonia 3
ES - Italia 3
RS - Serbia 3
AM - Armenia 2
AU - Australia 2
BY - Bielorussia 2
CL - Cile 2
IL - Israele 2
MD - Moldavia 2
MK - Macedonia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CM - Camerun 1
ID - Indonesia 1
LA - Repubblica Popolare Democratica del Laos 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
PH - Filippine 1
SG - Singapore 1
TN - Tunisia 1
TW - Taiwan 1
Totale 20.959
Salva come PNG Salva come JPEG
Città #
Fairfield 2.560
Woodbridge 1.760
Ashburn 1.305
Houston 1.246
Chandler 1.120
Ann Arbor 1.010
Seattle 1.001
Wilmington 903
Cambridge 854
Jacksonville 810
Dearborn 547
Beijing 311
Princeton 298
Dublin 287
Udine 186
Dong Ket 145
San Diego 139
Izmir 125
New York 95
Ogden 84
Des Moines 80
Hefei 55
Boardman 52
Norwalk 50
Ottawa 49
Brussels 45
Nanjing 43
Kunming 40
Codroipo 36
Washington 34
Lomé 30
Redmond 29
Falls Church 26
Martignacco 26
Guangzhou 24
Jinan 23
Phoenix 22
Warsaw 20
Los Angeles 19
Leawood 18
Milan 18
Timisoara 18
Trieste 18
Grafing 16
Nanchang 16
San Mateo 16
Zurich 16
Ardabil 15
Augusta 14
Helsinki 14
Monmouth Junction 14
Toronto 13
Wuhan 13
Hangzhou 12
Mcallen 11
Simi Valley 11
Rome 10
Hebei 9
Hong Kong 9
Naples 9
Nürnberg 9
Fremont 8
Chengdu 7
Fuzhou 7
Redwood City 7
Edinburgh 6
London 6
Mumbai 6
New Delhi 6
Padova 6
Shanghai 6
Treviso 6
Cairo 5
Deiva Marina 5
Frankfurt am Main 5
Indiana 5
Lappeenranta 5
Shenyang 5
Vienna 5
Andover 4
Auburn Hills 4
Baotou 4
Bogotá 4
Bovisio-Masciago 4
Casalecchio di Reno 4
Duncan 4
Leicestershire 4
Maserada Sul Piave 4
Menlo Park 4
Pesaro 4
Scafati 4
Tokyo 4
Venezia 4
Venice 4
Zhengzhou 4
Zoppola 4
Belgrade 3
Caserta 3
Changchun 3
Chongqing 3
Totale 15.974
Salva come PNG Salva come JPEG
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 172
Hepatitis B and cancer: A practical guide for the oncologist 163
BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress 145
Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making? 144
Role of pre-surgical breast MRI in the management of invasive breast carcinoma 141
Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers 140
Characterizing metastatic HER2-positive gastric cancer at the CDH1 haplotype 139
Bevacizumab in older patients with advanced colorectal or breast cancer 138
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 137
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 136
Role of mammography, ultrasound and large-core biopsy in the diagnostic evaluation of papillary breast lesions 134
Molecular diagnosis of neoplasms 133
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 131
Bone scanning in lung cancer: pretest probability is of value 130
Gene expression profiling in breast cancer: a clinical perspective. 129
B-cell lymphoma presenting as acute pancreatitis 128
Primary therapy in breast cancer: what have we learned from landmark trials? 128
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 128
D-dimer and venous thromboembolism 127
Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells 127
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 126
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy 125
Pattern of metastasis and outcome in patients with breast cancer 124
Expression of periostin in human breast cancer 122
Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story? 121
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 120
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. 119
Predictors of axillary lymph node metastases in patients with T1 breast carcinoma 117
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 117
Taxane-induced nail changes: incidence, clinical presentation and outcome 115
BRCA2 GERMLINE MUTATIONS IN PRIMARY CANCER OF THE FALLOPIAN TUBE 115
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer 114
Prognostic evaluation in palliative care: final results from a prospective cohort study 114
Hormone therapy in elderly breast cancer patients with comorbidities 113
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 113
Angiogenesis and tumor growth 112
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients 112
TSH controls ref-1 nuclear translocation in thyroid cells 111
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 111
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer 110
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 110
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study 110
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial 108
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 108
Vaccination for seasonal influenza in patients with cancer: Recommendations of the Italian Society of Medical Oncology (AIOM) 107
Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence 107
Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors 106
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 106
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 105
Follow-up of patients with early breast cancer: Is it time to rewrite the story? 105
p53 protein expression and p53 mutation in thymic epithelial tumors 104
Expert pathology consultation through the Internet: melanoma versus benign melanocytic tumours 104
What does similarity mean in clinical trials? 104
Galectin-3 expression in non-small cell lung carcinoma 104
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly 104
Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas 103
Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients 103
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 103
Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology 102
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 102
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 101
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. 100
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials 100
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole 100
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 100
From the podium to the patient: Bringing the 2008 ASCO meeting to the clinic 99
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer 99
Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients 99
Thymidine phosphorylase expression in metastatic kidney cancer as a potential predictor of outcome in patients treated with sunitinib 99
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 99
Balance between cell division and cell death as predictor of survival in patients with non-small-cell lung cancer 99
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 99
Tailoring adjuvant endocrine therapy for premenopausal breast cancer 98
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 98
Do platinum salts fit all triple negative breast cancers? 98
Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma 97
Looking for predictive markers in breast cancer 97
LOCALLY ADVANCED BREAST CANCER: COMPARISON OF MAMMOGRAPHY, SONOGRAPHY AND MR IMAGING IN EVALUATION OF RESIDUAL DISEASE IN WOMEN RECEIVING NEOADJUVANT CHEMOTHERAPY 97
MR mammography using diffusion-weighted imaging in evaluating breast cancer: a correlation with proliferation index 96
Capecitabine-induced cardiotoxicity: More evidence or clinical approaches to protect the patients' heart? 96
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 96
Current challenges in HER2-positive breast cancer 96
First-line chemotherapy with or without biologic agents for metastatic breast cancer 95
Treatment of HER2-positive breast cancer: current status and future perspectives 95
PROTEOMIC EVALUATION OF CORE BIOPSY SPECIMENS FROM BREAST LESIONS 95
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer 95
Markers of the uPA system and common prognostic factors in breast cancer 95
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 95
Sonographic criteria for differentiation of benign and malignant solid breast lesions: size is of value 94
Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report 93
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole 93
Telepathology using Internet Multimedia Electronic Mail: Remote Consultation on Gastrointestinal Pathology 93
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 93
Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma. 93
Determinants of Last-line Treatment in Metastatic Breast Cancer 93
CDK 4/6 inhibitors as single agent in advanced solid tumors 93
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. 92
Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly? 92
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 92
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 92
Totale 11.032
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.956
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.956
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.502 0 0 0 0 0 0 0 0 0 0 878 624
2019/20206.539 331 294 240 949 485 969 758 738 605 605 190 375
2020/20214.006 112 499 199 572 229 389 225 435 416 168 419 343
2021/20222.555 214 216 83 162 69 142 148 116 40 440 551 374
2022/20232.662 332 191 71 309 270 726 29 205 338 37 90 64
2023/20241.219 123 91 73 51 194 277 41 74 134 109 52 0
Totale 21.995